| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1+ lung adenocarcinoma harboring CCDC6–RET fusion gene and NF1/TP53 mutations
|
Nakasuka, Takamasa
|
|
|
156 |
C |
p. 1-4
|
artikel
|
| 2 |
Advances in the treatment of RET-fusion-positive lung cancer
|
Pall, Georg
|
|
|
156 |
C |
p. 136-139
|
artikel
|
| 3 |
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
|
Froesch, Patrizia
|
|
|
156 |
C |
p. 91-99
|
artikel
|
| 4 |
Contents
|
|
|
|
156 |
C |
p. iv-v
|
artikel
|
| 5 |
Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy
|
Lau, Sally C.M.
|
|
|
156 |
C |
p. 76-81
|
artikel
|
| 6 |
ETV6-NTRK3 translocation-associated low-grade mucinous bronchial adenocarcinoma: A novel bronchial salivary gland-type non-small cell lung cancer subtype
|
von der Thüsen, J.H.
|
|
|
156 |
C |
p. 72-75
|
artikel
|
| 7 |
Evaluation of disease staging and chemotherapeutic response in non-small cell lung cancer from patient tumor-derived metabolomic data
|
Miller, Hunter A.
|
|
|
156 |
C |
p. 20-30
|
artikel
|
| 8 |
Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017)
|
Chen, NaiBin
|
|
|
156 |
C |
p. 82-90
|
artikel
|
| 9 |
Influence of bilateral mediastinal lymph node dissection on survival in non-small cell lung cancer patients – Randomized study
|
Kużdżał, Jarosław
|
|
|
156 |
C |
p. 140-146
|
artikel
|
| 10 |
LC3A positive “stone like structures” are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma
|
Gachechiladze, M.
|
|
|
156 |
C |
p. 129-135
|
artikel
|
| 11 |
Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients
|
Soldath, Patrick
|
|
|
156 |
C |
p. 109-116
|
artikel
|
| 12 |
Lung carcinoid tumors with Diffuse Idiopathic Pulmonary NeuroEndocrine Cell Hyperplasia (DIPNECH) exhibit pejorative pathological features
|
Prieto, Mathilde
|
|
|
156 |
C |
p. 117-121
|
artikel
|
| 13 |
Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions
|
Larose, Frédéric
|
|
|
156 |
C |
p. 151-156
|
artikel
|
| 14 |
Microsimulation modeling of extended annual CT screening among lung cancer cases in the National Lung Screening Trial
|
Schreuder, Anton
|
|
|
156 |
C |
p. 5-11
|
artikel
|
| 15 |
Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer
|
Hsu, Chia-Lin
|
|
|
156 |
C |
p. 50-58
|
artikel
|
| 16 |
Performance insights of endobronchial ultrasonography (EBUS) and mediastinoscopy for mediastinal lymph node staging in lung cancer
|
Visser, M.P.J.
|
|
|
156 |
C |
p. 122-128
|
artikel
|
| 17 |
Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis
|
Horiuchi, Kohei
|
|
|
156 |
C |
p. 59-67
|
artikel
|
| 18 |
Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902)
|
Ito, Shotaro
|
|
|
156 |
C |
p. 12-19
|
artikel
|
| 19 |
Prognostic index for estimating the survival benefit of postoperative radiotherapy in pathologic N2 non–small cell lung cancer: A real-world validation study
|
Zhang, Chen-Chen
|
|
|
156 |
C |
p. 100-108
|
artikel
|
| 20 |
Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer
|
Waterhouse, David
|
|
|
156 |
C |
p. 41-49
|
artikel
|
| 21 |
Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond
|
Joshi, Kroopa
|
|
|
156 |
C |
p. 147-150
|
artikel
|
| 22 |
Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors – The Ontario experience
|
Tammemägi, Martin C.
|
|
|
156 |
C |
p. 31-40
|
artikel
|
| 23 |
Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538
|
Bogart, Jeffrey A.
|
|
|
156 |
C |
p. 68-71
|
artikel
|
Tijdschrift beschrijving